The average age of men who get diagnosed is 67.
Early trials of the drug VIR-5500 showed it shrinking tumours in some patients ...
Significantly less progression, especially unstable lesions, with relugolix versus leuprol ...
One type of androgen deprivation therapy may speed coronary plaque growth in men being treated for localized prostate cancer.
The treatment, a type of immunotherapy which harnesses the body’s immune system to fight cancer, was found to shrink tumours or halt their growth.